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Introduction
Human immunodeficiency virus (HIV) infection continues to be a 
major global health problem; a 2011 estimate indicates that 23.5 million 
people living with HIV resided in sub-Saharan Africa, which represents 
69% of the global HIV burden [1]. Also in 2011, 8.7 million people 
became ill with tuberculosis (TB) of which 1.4 million died [2]. There 
were about 1.1 million new cases of HIV-positive new TB cases with 
79% of them living in Africa and globally about 430,000 people died of 
HIV-associated TB [2].
Advanced immune suppression remains the most important risk 
factor for tuberculosis in those with HIV [3], but epidemiological and 
clinical factors have also been identified [4,5]. We previously evaluated 
risk factors for TB in our population of adult patients on antiretroviral 
therapy (ART) and noted that poor immunologic and/or virologic 
response to ART and male sex were some of the risk factors for TB in 
ART patients [6]. However, we do not know if such risk factors differ in 
pre-ART patients. 
Pulmonary tuberculosis (PTB) is predominantly responsible for 
TB transmission in human populations [7,8]. Prevalence and known 
risk factors for PTB among HIV-infected adults vary from one setting 
to another [5,9,10]. Identification of the factors associated with PTB-
HIV co-infection in pre-ART HIV patients could have implications for 
clinical management and TB control strategies. 
In this study, we determined the factors associated with PTB co-
infection in a cohort of ART-naive HIV-infected patients presenting to 
the AIDS Prevention Initiative in Nigeria (APIN)-supported HIV clinic 
at the Jos University Teaching Hospital (JUTH), Jos.
Methods
Study setting/population
The study was carried out at the HIV clinic at the Jos University 
Teaching Hospital, Jos; the care and treatment program has been 
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supported by the U.S. President’s Emergency Plan for AIDS Relief 
(PEFPAR) since 2004. This clinic provides comprehensive HIV 
care services for the city of Jos, which is located in Jos North Local 
Government Area (LGA) of Plateau State. The clinic also serves as a 
referral centre for health facilities in other LGAs of the state and even 
other states in the region. In a 2006 census, the population of Plateau 
State was 3,206,531, with the capital city of Jos having a population 
of approximately 900,000. All HIV-related clinic, pharmacy and 
laboratory data for the enrolled patients are maintained in electronic 
databases at the site.
Study design
This was a cross-sectional study in which data on 218 consecutive 
adult patients (≥ 15 years) accessing care at the adult ART clinic over 
a 7-month period from October 2010 – April 2011 were evaluated. All 
patients included in the study provided written informed consent for 
the use of their data for research as approved by the institutional review 
boards at the Jos University Teaching Hospital, APIN Ltd. and Harvard 
School of Public Health. Patients who were on TB treatment prior to 
presentation were excluded from the study. All newly diagnosed HIV-
infected persons initiating care in the clinic were routinely screened for 
TB using symptoms and chest radiographs. Those with chronic cough 
(≥ 2 weeks), in addition had sputum smear microscopy using Ziehl-
Neelsen (Z-N) stain for the Mycobacterium tuberculosis (Mtb) acid-fast 
bacilli (AFB). Other radiologic and histologic tests were carried out 
where indicated. Culture and molecular diagnostic facilities for TB 
were not available at the time of this study. The analyses utilized data 
that were already being captured in an electronic data management 
system as a part of ongoing Harvard/APIN PEPFAR Program. The 
data accessed for the 218 subjects included: demographic (age, sex, 
residence, education level, occupation, marital status, mode of HIV 
transmission, spouse HIV status, spouse ARV treatment status), 
clinical (WHO HIV clinical stage, oropharyngeal candidiasis, chronic 
diarrhoea and Kaposi's sarcoma (KS)) and laboratory (hepatitis b virus 
(HBV) status, viral load and CD4 cell count) variables.
All laboratory tests were done as a part of the existing treatment 
program; no additional laboratory analyses were done for the purposes 
of the analyses described here. HIV serodiagnosis was conducted using 
two different rapid HIV tests: Uni-Gold (Trinity Biotech Plc Bray Co 
Wicklow, Ireland) and Determine HIV-1/2 test (Determine Alere 
Medical Co., Ltd 357 Matsuhidai, Japan). CD4+ lymphocyte count was 
measured by flow cytometry (Partec GmbH, Munster Germany) and 
HIV-1 RNA viral load was measured using the Roche Cobas Amplicor 
HIV-1 Monitor, version 1.5 (Roche Diagnostics GmbH, Mannheim, 
Germany). HBsAg was determined using Enzyme Immunoassay (EIA) 
(Monolisa HBsAg Ultra3; Bio-Rad).
Case definitions
In our study, all patients with positive sputum AFB smears were 
classified as having PTB. In persons with negative AFB smears, a 
diagnosis of smear negative PTB was made in line with the World 
Health Organization’s recommendation if a TB suspect had a chest 
radiograph consistent with PTB [11]. A patient with both PTB and HIV 
at the time of care was considered a case of PTB-HIV co-infection.
Statistical methods
All of the analyses were performed using Stata software version 
10.1 (Stata Corporation, College Station, Texas, USA). Univariate 
associations of each independent variable with PTB-HIV co-infection 
were examined using the Fisher’s exact test for categorical variables 
and the Wilcoxon signed rank test for continuous variables, as these 
variables were not normally distributed. In the univariate analysis, the 
continuous variables were categorized as follows: age into four groups 
based on quartile distribution; CD4+ cell count into four groups (based 
on clinical relevance and also using the WHO cut-off value of 200 cells/
mm3 [3]); and, RNA viral load into 3 groups based on clinical relevance 
and log categories. All tests were two-sided and a p-value of 0.05 was 
considered significant.
Following the results of the univariate analyses, the following 
predictor variables were further stratified: age (≤ 34 years versus >34 
years), education level, marital status, WHO clinical stage (stage 3 or 4 
versus stages 1 or 2) HIV RNA viral load (<5.0 versus ≥ 5 log10 copies/
mL) and CD4+ cell count (≤ 100 cells/mL versus >100 cells/mL). We 
used 34 years cut-off for stratifying age into two groups as that was the 
median value for the age variable. And for the CD4 count variable, the 
100 cells/mL value was the point at which we saw the main difference. 
We had previously left the 3 categories and found that leaving it as 3 
categories took away from the strength of the final model and that 
using the 100 cells/mL cut-off made it a stronger predictor variable. 
Thus, collapsing the age and CD4 count variables subsequently gave us 
a more parsimonious model with fewer degrees of freedom.
Univariate and multivariate logistic regression models were fitted 
to determine the factors associated with PTB-HIV co-infection, 
which were expressed as an odds ratio. Variables were considered for 
inclusion in the multivariate model if they were found associated with 
the risk of co-infection in the univariate analyses at p<0.20. Sex and age 
were included a priori in the multivariate model since many disease 
processes, including PTB and HIV, are often influenced by age and sex. 
A backward stepwise modelling strategy was used in building the final 
multivariate model. The area under the receiver operating characteristic 
(ROC) curve was also determined to assess the performance of our 
model.
Results
Of the 218 HIV-1 infected adult patients, 21 (9.6%) had PTB-
HIV co-infection. In the cohort, a majority (60.1%) were females, in 
the younger (<35 years) age group (50.9%), residents of Plateau State 
(64.7%), had secondary level education or greater (67.9%), were 
employed (76.1%) and married (65.6%). In the cohort, 47.2% had an 
HIV-positive spouse, and 10.1% of those spouses were on ARV drugs. 
The predominant mode of transmission was heterosexual sex (97.7%). 
At the time of presentation, 56.3% of subjects were diagnosed as being 
WHO clinical stage 3 or 4, 6.4% had HBV co-infection, 20.6% had 
oropharyngeal candidiasis, 16.1% had chronic diarrhoea and 3.7% had 
Kaposi’s sarcoma. 
In univariate analyses, patients with HIV-PTB co-infection were 
more likely than those with HIV mono-infection to be diagnosed with 
WHO stage 4 (61.9% vs. 18.0%; p<0.001) be HBV positive (19.1% 
vs. 5.1%; p=0.03); have oropharyngeal candidiasis (52.4% vs 17.3%; 
p=0.001); and, report chronic diarrhoea (42.9% vs. 13.2%; p=0.002). 
The median HIV viral load was higher in those with PTB co-infection 
compared to those with HIV alone (5.0 log10 copies/mL (4.4-6.0) versus 
4.6 log10 copies/mL (4.2-5.0); p=0.03). The median CD4+ cell count was 
significantly lower in those with PTB co-infection compared to those 
with HIV alone (53 cells/mL (IQR: 31-93) versus 201 cells/mL (IQR: 
115-291); p<0.0001). There were no subjects (0.0%) with PTB-HIV co-
infection with a CD4+cell count above the cut-off level (200/mm3) for 
severe immune suppression (Table 1). 
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In the unadjusted logistic regression analyses, WHO HIV clinical 
stage 3/4, HBV positivity, presence of oropharyngeal candidiasis and 
chronic diarrhoea were all significantly associated with PTB-HIV co-
infection (OR: 8.68, 4.4, 5.27 and 4.93, respectively). The odds of having 
PTB-HIV co-infection was 2.91 times more in those with HIV RNA 
viral load of ≥5.0 log10 cp/mL as compared to those with less (p=0.02) 
while the odds of having PTB-HIV co-infection was 9% lower in those 
with CD4+ cell counts >100 cells/mL as compared to those with ≤100 
cells/mL (p<0.001) (Table 2). 
In the multivariate analyses, CD4+ cell count was significantly 
associated (p=0.002) with PTB-HIV co-infection, with the odds of 
co-infection reduced by 85% in those with a count >100 cells/mm3 
compared to those with a count <100 cells/mm3. In addition, patients 
with oropharyngeal candidiasis were found to be nearly 4.5 times more 
likely to have PTB-HIV co-infection than those without candidiasis 
(p=0.008) (Table 2). In our final model, no association was observed 
between WHO clinical stage, HBV status and chronic diarrhoea and 
PTB-HIV co-infection, respectively, as was seen in the univariate 
analyses; WHO clinical stage and HBV status remained in the final 
model as they act as effect modifiers in the independent associations 
of CD4+ cell count and oropharyngeal candidiasis with PTB-HIV co-
infection. The area under the ROC curve for our final model was 0.88.
Discussion
In this study, we found a PTB frequency of 9.6% among HIV-infected 
adults presenting in our HIV clinic. CD4+ cell count (≤100 cells/mL) and 
oropharyngeal candidiasis were found to be independently associated 
with PTB-HIV co-infection, with WHO clinical stage and HBV status 
acting as effect modifiers in multivariate modeling. The area under 
the ROC curve of 0.88 suggests that the final multivariate model we 
obtained fitted the data very well and thus helped to confirm the 
validity of our model.
Bassett et al. reported a PTB-HIV co-infection prevalence of 19% 
in Durban, South Africa, which is much higher than our PTB-HIV co-
infection frequency of 9.6% [12]. The global prevalence of PTB-HIV is 
reported to be 0.18% [13], which is lower than the 9.6% for our study. 
The differences in PTB prevalence rates in other populations compared 
to ours are likely due to true differences in the burden of TB in these 
communities.
The association of lower CD4+ cell counts, especially counts 
≤100 cells/mL with PTB-HIV co-infection observed in our study is as 
expected; it is well recognized that the risk of opportunistic infections, 
including TB, in persons with HIV increases markedly when CD4+ 
cell counts drops below 200 cells/mm3 [3,6,14]. Depletion of CD4+ 
T cells seen in advanced HIV disease impairs host response to Mtb; 
particularly granuloma formation hence facilitating progression of 
recent infection as well as reactivation of latent TB to active disease 
[15].This lower CD4+ cell count could also explain our finding of the 
association between oropharyngeal candidiasis and PTB-HIV co-
infection. 
Although not statistically significant in the multivariate analysis, 
there was a trend for increased odds of PTB-HIV co-infection in men 
despite a preponderance of women in our study. Several studies have 
shown that male gender was associated with TB-HIV co-infection [16]. 
This association might further be explained by the X chromosome 
susceptibility gene contributing to excess of males with TB in some 
African populations as suggested by Bellamy et al. [17].
One of the limitations of our study is the small study population; 
Characteristics
Total PTB-HIV co-infection
HIV mono-
infection P value*
N (%) N (%) N (%)
Age (yrs)
     <29
     29-34
     35-41
     >41
     Median (IQR)
56 (25.7)
55 (25.2)
56 (25.7)
51 (23.4)
34 (28-41)
5 (23.8)
6 (28.6)
5 (23.8)
5 (23.8)
34 (28-41)
51 (25.9)
49 (24.9)
51 (25.9)
46 (23.3)
34 (29-41)
0.98
      
0.96**
Sex
     Male
     Female
87 (39.9)
131 (60.1)
12 (51.7)
9 (42.9)
75 (38.1)
122 (61.9) 0.10
Residence
     Plateau
     Others
141 (64.7)
77 (35.3)
16 (76.2)
5 (23.8)
125 (63.5)
72 (36.6)
0.34
Education level
     None
     Primary
     Secondary
     Tertiary
21 (9.6)
49 (22.5)
79 (36.2)
69 (31.7)
0 (0.0)
6 (28.6)
6 (28.6)
9 (42.8)
21 (10.7)
43 (21.8)
73 (37.1)
60 (30.4) 0.27
Occupation
     Student
     Unemployed
     Employed
19 (8.6)
30 (15.2)
150 (76.1)
2 (9.5)
1 (4.8)
18 (85.7)
17(18.6)
30 (15.2)
150 (76.1)
0.51
Marital status
     Married
     Widowed
     Divorced/ Separated
     Single
143 (65.6)
16 (7.3)
15 (6.9)
44 (20.2)
14 (66.7)
2 (9.5)
0 (0.0)
5 (23.8)
129 (65.5)
14 (7.1)
15 (7.6)
39 (19.8)
0.66
Spouse HIV status
     Positive
     Negative
103 (47.2)
115 (52.8)
13 (61.9)
8 (38.1)
90 (45.7)
107 (54.3)
0.17
Spouse on ARV drugs
     On ARV
     Not on ARV
22 (10.1)
196 (89.9)
0 (0.0)
21 (100.0)
22 (11.2)
175 (88.8)
0.14
Mode of HIV transmission
     Heterosexual
     Blood transfusion
213 (97.7)
5 (2.3)
20 (95.2)
1 (4.8)
193 (98.0)
4 (2.0)
0.40
WHO clinical stage
     1
     2
     3
     4
39 (19.6)
48 (24.1)
67 (33.7)
45 (22.6)
0 (0.0)
2 (9.5)
6 (28.6)
13 (61.9)
39 (21.9)
46 (25.8)
61 (34.3)
32 (18.0)
<0.001
HBV status
     Positive
     Negative
14 (6.4)
204 (93.6)
4 (19.1)
17 (80.9)
10 (5.1)
187 (94.9)
0.03
Oropharyngeal candidiasis
     Present
     Absent
45 (20.6)
173 (79.4)
11 (52.4)
10 (47.6)
34 (17.3)
163 (82.7)
0.001
Chronic diarrhoea
     Present
     Absent
35 (16.1)
183 (83.9)
9 (42.9)
12 (57.1)
26 (13.2)
171 (86.8)
0.002
Kaposi's sarcoma
     Present
     Absent
8 (3.7)
210 (96.3)
1 (4.8)
20 (95.2)
7 (3.5)
190 (95.5)
0.56
HIV RNA Log viral load 
(copies /ml)
     <4.0
     4.0-4.9
     > 5.0
     Median (IQR)
 31 (14.2)
122 (56.0)
65 (29.8)
4.6(4.2-5.0)
2 (9.5)
8 (38.1)
11 (52.4)
5.0 (4.4-6.0)
29 (14.7)
114 (57.9)
54 (27.4)
4.6 (4.2-5.0)
0.08
0.03
CD4 count (per  mm3)
     ≥5.0
     51-100
     101-200
     >200
     Median (IQR)
30 (13.8)
29 (13.3)
60 (27.5)
99 (45.4)
185 (92 – 280)
10 (47.6)
6 (28.6)
5 (23.8)
0 (0.0)
53 (31-93)
20 (10.2)
23 (11.7)
55 (27.9)
99 (50.2)
201 (115-291)
<0.001
*Fisher’s exact test for the association between categorical variables and PTB-HIV 
co-infection [20]
**Wilcoxon rank sum test for comparison of median values
Table 1: Characteristics of Adults Initiating HIV Care at JUTH by PTB-HIV Co-
infection Status.
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were cases of advanced HIV disease that were complicated by PTB. Late 
presentation of HIV-infected patients in our environment often results 
in unfavourable clinical outcomes due to a poorer immune recovery 
following treatment in those with long-standing HIV infection [18,19]. 
In addition, the increased PTB-HIV co-infection in the patients with 
the most severe HIV disease may increase the risks for further PTB 
transmission, particularly in hospital settings.
Conclusion
Pulmonary TB was prevalent among newly diagnosed HIV 
patients in our setting. Severe immune suppression and oropharyngeal 
this may explain the loss of association between WHO clinical stage and 
PTB-HIV co-infection (p=0.06) in multivariate analyses, despite this 
being significant in the univariate analysis (p<0.001). Another limitation 
is the generalizability of our study and the observed prevalence; since 
our study was health facility-based, it is biased towards having a higher 
prevalence than the general population.
It is expected that most PTB-HIV co-infected patients would have 
severe immune suppression. In our study, none (0.0%) of the patients 
with PTB-HIV co-infection had a CD4+ cell count above the clinical 
cut-off value (200/mm3), indicating that all of the co-infected patients 
Predictor Crude OR  (95%CI) P Value Adjusted OR** (95% CI) P Value
Age (yrs)
     <34
     ≥34
10 (Ref)
0.93 (0.38-2.31) -
0.88
1.00 (Ref)
0.68 (0.22-4.26)
-
0.51
Sex
     Female
     Male
1.00 (Ref)
2.17 (0.87-5.39)
-
0.096
1.00 (Ref)
1.38 (0.43-4.26
0.60
Residence
     Others
     Plateau
1.00 (Ref)
1.84 (0.65-5.24)
-
0.25
Education level
     None/ Primary
     Secondary/ Tertiary
1.00 (Ref)
1.20 (0.45-3.25)
-
0.72
Occupation
     Student
     Unemployed
     Employed
1.00 (Ref)
0.28 (0.02-3.36)
1.02 (0.22-4.78)
-
0.32
0.98
Marital status
     Married
     Widowed/Divorced/ Separated
     Single
1.00 (Ref)
0.64 (0.14-2.95)
1.18 (0.40-3.39)
-
0.56
0.76
Spouse HIV status
     Negative
     Positive
1.00 (Ref)
1.93 (0.77-4.87)
-
0.16
Spouse on ARV
     Not on ARV
         On ARV
1.00 (Ref)
Predicts failure perfectly*
Mode of HIV transmission
     Heterosexual
     Blood transfusion
0.41 (0.04-3.89)
1.00 (Ref)
0.44
-
WHO clinical stage
     1/2  
     3/4 
1.00 (Ref)
8.68 (1.96-38.4)
-
0.004
1.00 (Ref)
3.54 (0.72-17.42)
-
0.12
HBV status
     Negative
     Positive
1.00 (Ref)
4.4 (1.25-15.5)
-
0.02
1.00 (Ref)
4.20 (0.92-19.12)
-
0.06
Oropharyngeal candidiasis
     Absent
     Present
1.00 (Ref)
5.27 (2.08-13.40)
-
<0.001
1.00 (Ref)
4.56 (1.48-14.03)
-
0.008
Chronic diarrhoea
     Absent
     Present
1.00 (Ref)
4.93 (1.89-12.85)
-
0.001
Kaposi's sarcoma
     Absent
     Present
1.00 (Ref)
1.36 (0.15 (11.60)
-
0.78
HIV RNA Log viral load (copies /ml)
     <5.0
     ≥5.0
1.00 (Ref)
2.91 (1.17-7.25)
-
0.02
CD4 count (per mm3)
     ≤100
     >100
1.00 (Ref)
0.09 (0.03-0.25)
-
<0.001
1.00 (Ref)
0.15 (0.05-0.49) 0.002
*Stata did not provide the CI because there were no subjects on ARV in those without PTB-HIV co-infection
**All predictors with p<0.20 were considered for inclusion in the final model. Adjusted ORs for predictors that remained in final model are shown. Chronic diarrhoea and viral 
load dropped out as significant predictors in the final model.
Table 2: Predictors of PTB-HIV co-infection.
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candidiasis were independently associated with PTB-HIV co-infection. 
Potential implications for severe immune suppression and advanced 
HIV disease are poor clinical outcomes and further spread of PTB. 
Strategies to encourage the early diagnosis of both HIV and TB should 
be considered. 
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